'Single agent' diaporamas de présentation

BTK inhibition in mantle cell and diffuse large cell lymphoma: the next steps

BTK inhibition in mantle cell and diffuse large cell lymphoma: the next steps. Kristie A. Blum, MD Associate Professor of Medicine Section Head, OSU Lymphoma Program. Discussion topics. Single agent ibrutinib trials Combination ibrutinib trials Prognostic factors in MCL and DLCL

984 views • 74 slides

CS 8520: Artificial Intelligence

CS 8520: Artificial Intelligence. Intelligent Agents and Search Paula Matuszek Fall, 2005. Slides based on Hwee Tou Ng, aima.eecs.berkeley.edu/slides-ppt, which are in turn based on Russell, aima.eecs.berkeley.edu/slides-pdf. Outline. Agents and environments Rationality

895 views • 62 slides

Revisions to the FCDS Data Set NAACCR V10

Revisions to the FCDS Data Set NAACCR V10. Mayra Alvarez, RHIT, CTR Megsys Casuso, CTR Mark Rudolph, MS Jill MacKinnon, CTR. Effects of V10. Implications for all of us Conversion of data Some fields Layout Implementation of new software Learning new codes and rules (FORDS).

727 views • 52 slides

Hyperhomocysteinemia A New Cardiac Risk Factor?

Hyperhomocysteinemia A New Cardiac Risk Factor?. Michael Pursley M.D. Resident Grand Rounds January 26, 1999. CASE PRESENTATION. HPI: 42 wm transferred to NCBH secondary to newly dx nqwmi. CRF: Negative, except for FH PMHX: Non significant MEDS: None SOC: negative tobacco, occ. ETOH

796 views • 47 slides

Company Analysis: MLNM

Company Analysis: MLNM. Andrea Hooper Imke Ehlers Rana Sawaya Carlos Dedesma. Carlos. What Were Our Data Sources?. Carlos. What are they Worth?. Introduction Assets Some Product; Lots of Pipeline Agreements. Carlos. What are they Worth?. Introduction Assets

712 views • 42 slides

Virtual Machine Protection Advanced and modern protection technology designed specifically for virtual environments

615 views • 42 slides

Multiple Sclerosis: An evolving treatment landscape

Multiple Sclerosis: An evolving treatment landscape. Oklahoma Academy of Physician Assistants 40 th Annual Conference Gabriel Pardo, MD OMRF Multiple Sclerosis Center of Excellence. Disclosures. Gabriel Pardo , MD Director Multiple Sclerosis Center of Excellence

719 views • 41 slides

Princess Nora University Artificial Intelligence

Princess Nora University Artificial Intelligence. CS 461 Level 8. Chapter 2: Intelligent Agents . Out Line : Agents and environments Rationality PEAS Environment types Agent typ es. Agent (1).

575 views • 37 slides

Intelligent Agents

Intelligent Agents. CHAPTER 2 Oliver Schulte Summer2011. Outline. Agents and environments Rationality PEAS (Performance measure, Environment, Actuators, Sensors) Environment types Agent types. Agents.

746 views • 34 slides

Overlapping Coalition Formation: Charting the Tractability Frontier

Overlapping Coalition Formation: Charting the Tractability Frontier. Y. Zick , G. Chalkiadakis and E. Elkind (submitted to AAMAS 2012). Motivation. Agents have limited integer resources. Form Bilateral Trade Contracts : coalitions. The benefit of interaction may be freely divided.

450 views • 34 slides

Drug/Diagnostic Co-Development

478 views • 33 slides

Hypertension-so what has changed? Review of ASCOT and NICE Guidelines

Hypertension-so what has changed? Review of ASCOT and NICE Guidelines. Cardiovascular Study day Cheltenham Racecourse 10 th October 2006 Dr Jim Moore. ASCOT- BPLA: Rationale.

469 views • 32 slides

Intelligent Agents

Intelligent Agents. Chapter 2. Agents. An agent is anything that can be viewed as perceiving its environment through sensors and acting upon that environment through actuators Human agent: eyes, ears, and other organs for sensors; hands,

318 views • 22 slides

1 Richardson PG et al. Proc ASH 2011;Abstract 301. 2 Kumar S et al. Proc ASH 2011 ; Abstract 816. 3 Berdeja JG et a

198 views • 19 slides

RISK MANAGEMENT FOR SALESPERSONS

255 views • 19 slides

Tactical Combat Casualty Care Guideline Change 14-03

Tactical Combat Casualty Care Guideline Change 14-03. Ondansetron. 02 Dec 14. Analgesia Notes ( cont )

355 views • 16 slides

One-to-n Scrip Systems for Cooperative Privacy-Enhancing Technologies

EPFL - Laboratory for Communications and Applications (LCA1). One-to-n Scrip Systems for Cooperative Privacy-Enhancing Technologies. Allerton 2011 September 28 . Mathias Humbert , Mohammad Hossein Manshaei , and Jean-Pierre Hubaux. Privacy-Enhancing Technologies ( PETs ).

149 views • 14 slides

Proposed Design Change

317 views • 13 slides

Placebo: Why and why not?

Placebo: Why and why not?. Group Four Mariam Ahmed, Irine Jepchirchir, Dylan Galos, Lucie Turcotte, Chris Campbell, Junghi Kim, and Brett Peterson. Placebo. An inactive agent, used in the study control arm, to maintain blinding in a clinical trial

224 views • 11 slides

NSCLC, non-small cell lung cancer.

NSCLC treatment guidelines: National Comprehensive Cancer Network and European Society for Medical Oncology. NSCLC, non-small cell lung cancer.

514 views • 8 slides